Evotec Extends Integrated Drug Discovery Alliance with Genentech

HAMBURG, Germany--()--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that Genentech, a member of the Roche Group, has extended its integrated drug discovery alliance with Evotec for a further three years to discover novel small molecule therapeutics.

The collaboration initiated in May 2010 was renewed in 2013 and this second extension further validates the value of Evotec's state-of-the-art technology platform and broad expertise in drug discovery. Activities performed within the collaboration include pharmacology, screening, chemistry, proteomics and structural biology.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are delighted that once again we have extended this fruitful collaboration beyond its 7th year and this latest extension is validation of the value Evotec brings to this partnership. With an increasing portfolio of activities, the scientific teams from both companies are working closely together to effectively and efficiently advance Genentech's discovery projects."

No financial details were disclosed.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's disease, with MedImmune and Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and with Second Genome in the field of inflammatory diseases. For additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Language:   English
 
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
 
Phone: +49 (0)40 560 81-0
 
Fax: +49 (0)40 560 81-222
 
E-mail:

info@evotec.com

 
Internet:

www.evotec.com

 
ISIN: DE0005664809
 
WKN: 566480
 
Indices: TecDAX
 
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart; Terminbörse EUREX

Contacts

Contact Evotec AG
Gabriele Hansen, +49.(0)40.56081-255
VP Corporate Communications & Investor Relations
gabriele.hansen@evotec.com

Recent Stories

RSS feed for Evotec AG

Evotec AG